| Clinical Trial ID NCT01642290

Clinical Trial ID NCT01642290

Rank	Title	Journal	Year	PubWeight™‹?›
1	Agonist antibodies to TNFR molecules that costimulate T and NK cells.	Clin Cancer Res	2013	1.33
2	Intratumoral immunization: a new paradigm for cancer therapy.	Clin Cancer Res	2014	1.24
3	PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.	PLoS One	2014	1.13
4	The immune system and inflammation in breast cancer.	Mol Cell Endocrinol	2013	1.12
5	Combinations of immunotherapy and radiation in cancer therapy.	Front Oncol	2014	1.01
6	Novel antibodies targeting immune regulatory checkpoints for cancer therapy.	Br J Clin Pharmacol	2013	0.94
7	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.	J Immunother Cancer	2014	0.87
8	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.	J Transl Med	2013	0.85
9	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.	Cancer	2013	0.83
10	Current clinical trials testing the combination of immunotherapy with radiotherapy.	J Immunother Cancer	2016	0.81